Top Abstract Purchase Related
Home
>
Node
>
Subnode

Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas

Broholm, H.; Bols, B.; Heegaard, S.; Braendstrup, O.

Clinical Neuropathology 18(4): 176-180

1999

ISSN/ISBN: 0722-5091
PMID: 10442459
Document Number: 508649
The biological behavior of oligodendrogliomas is somewhat unpredictable. A supplementing prognostic factor is, therefore, desirable. Thirty-two supratentorial pure oligodendrogliomas were studied immunohistochemically by exposing the tumors to a monoclonal antibody towards the p53 protein, and a polyclonal antibody against the epidermal growth factor receptor (EGFR). A mean p53 labeling index (% of tumor cells stained) of 8.6% and a weak EGFR expression in 18 of the oligodendrogliomas were found. Univariate analysis showed no correlation between p53, EGFR expression and prognosis. Multivariate analysis showed that age was a prognostic factor for survival.

Document emailed within 1 workday
Secure & encrypted payments

Kondi-Pafiti, A.; Kairi-Vassilatou, E.; Frangou-Plemenou, M.; Dimopoulou, C.; Englezou, M.; Sykiotis, K. 2002: Immunohistochemical investigation of p-53, C-NEU and EGFR expression in HPV-related epidermoid endometrial carcinoma European Journal of Gynaecological Oncology 23(1): 70-71
Kogan, E.A.; Rozhkova, E.B.; Seredin, V.P.; Paltsev, M.A. 2006: Prognostic value of the expression of thyreoglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies Arkhiv Patologii 68(4): 8-11
Wistuba, I.; Roa, I.; Araya, J.; Villaseca, M.; Chávez, F.; Capurro, I. 1994: Immunohistochemical expression of epidermal growth factor receptor (EGFR) in epidermoid carcinoma of the cervix uteri and its precursor lesions Revista Chilena de Obstetricia y Ginecologia 59(2): 116-122
Shepherd, F.A. 2016: Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients Clinical Advances in Hematology and Oncology: H&o 14(1): 41-43
Cirillo, M.; Lombardi, C.; Chiricone, D.; Bilancio, G.; Marcarelli, F.; De Santo, N.G. 2008: Early identification of kidney disease by eGFR: what is the prevalence of eGFR in the population? Journal of Nephrology 21(Suppl 13): S102-S106
Yano, S.; Kondo, K.; Yamaguchi, M.; Richmond, G.; Hutchison, M.; Wakeling, A.; Averbuch, S.; Wadsworth, P. 2003: Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Research 23(5a): 3639-3650
Hirano, S.; Takeda, Y.; Hiraishi, Y.; Higashino, M.; Nakamichi, S.; Ishii, S.; Naka, G.; Iikura, M.; Izumi, S.; Sugiyama, H.; Kobayashi, N. 2012: Efficacy of combination therapy with EGFR-TKi and cytotoxic drug in lung adenocarcinoma already treated with EGFR-TKi Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(2): 213-219
Jin, B.; Zhang, Y.; Zhang, X.; Li, R.; Lou, Y.; Niu, Y.; Huang, A.; Han, B. 2014: Value of carcinoembryonic antigen levels in predicting the efficacy of EGFR-TKi in advanced non-small cell lung cancer harboring EGFR mutations Zhonghua Yi Xue Za Zhi 94(30): 2327-2331
Cunningham, M.P.; Thomas, H.; Marks, C.; Green, M.; Fan, Z.; Modjtahedi, H. 2008: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells International Journal of Oncology 33(5): 1107-1113
Li, J.; Hong, Q.; Zhang, X.; Hu, J.; Bai, C. 2014: Therapeutic efficacy and safety of chemotherapy subsequent EGFR-TKi in advanced non-small cell lung cancer patients with EGFR-TKi acquired resistance Zhonghua Yi Xue Za Zhi 94(30): 2342-2345
El Hamdani, W.; Amrani, M.; Attaleb, M.; Laantri, N.; Ennaji, M.M.; Khyatti, M.; El Mzibri, M. 2010: EGFR, p16INK4a and E-cadherin immuno-histochemistry and EGFR point mutations analyses in invasive cervical cancer specimens from Moroccan women Cellular and Molecular Biology 56 Suppl: Ol1373-Ol1384
Vargas Cruz, V.; García Ceballos, A.; Ruiz Hierro, C.; Moreno Rodríguez, M.M.; Escassi Gil, A.; Garrido Pérez, J.I.; Paredes Esteban, R.M. 2010: Structural alterations of the smooth muscle and of the EGFR expression and C-kit in congenital pyeloureteral stenosis. Relationship with its pathogenesis Cirugia Pediatrica: Organo Oficial de la Sociedad Espanola de Cirugia Pediatrica 23(2): 82-87
Kordek, R.; Bratosiewicz, J.; Biernat, W.; Alwasiak, J.; Liberski, P.P. 1994: Expression of p53-protein, epidermal growth factor receptor (EGFR) and proliferating cell antigens in human gliomas Folia Neuropathologica 32(4): 227-228
Misiakos, E.P.; Agrogiannis, G.; Patapis, P.; Dontas, I.; Petropoulos, K.; Machairas, N.; Giamarellos-Bourboulis, E.; Liakakos, T.; Machairas, A. 2013: Expression of tissue IGF 1, TGFbeta and EGFR in the sequential steps of intestinal adaptation in a rat model of short bowel syndrome Acta Chirurgica Belgica 113(2): 129-138
Sobande, F.; Dušek, L.; Matějková, A.él.; Rozkoš, T.áš; Laco, J.; Ryška, A.š 2015: EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number Ceskoslovenska Patologie 51(2): 80-86
Balboni, G.C.; Barni, T.; Serio, M.; Vannelli, G.C. 1991: Plasminogen activator and inhibin in the human testis. An immunohistochemical investigation Bulletin de l'Association des Anatomistes 75(228): 123-126
Hori, M.; Furusato, M.; Aizawa, S.; Tanaka, H.; Uchida, K. 1990: An immunohistochemical investigation of estrogen receptor in human breast cancer Gan no Rinsho. Japan Journal of Cancer Clinics 36(2): 143-147
Wagenblast, J.; Hambek, M.; Baghi, M.; Knecht, R. 2008: Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines Anticancer Research 28(2a): 687-692
Liu, H.; Han, D.; Zheng, L. 1996: Investigation of infiltrating lymphocytes and immunoglobulin by immunohistochemical method in cheilitis granulomatosa Zhonghua Kou Qiang Yi Xue Za Zhi 31(1): 45-47
Wang, L.; Zhang, X.; Wang, Z-Yi. 2010: The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance Anticancer Research 30(9): 3637-3642